Akero Therapeutics reports Q2 2025 cash of $1.09B; Phase 2b MASH cirrhosis data published in NEJM

Akero Therapeutics, Inc.

2025-Q2 EPS reported -$1.76

Cash, equivalents and marketable securities of $1,086.2M at June 30, 2025; expected to fund operations into 2028.
R&D expenses $69.3M (Q2 2025) vs $55.3M (Q2 2024), driven by Phase 3 SYNCHRONY trials and clinical supplies.
Total operating expenses $80.9M vs $65.7M year-over-year; G&A up to $11.6M from $10.4M.
Phase 2b SYMMETRY trial results published in NEJM; EFX 50mg reversed cirrhosis in high-need subgroups.
Preliminary Phase 3 SYNCHRONY Real-World data expected H1 2026; Histology readout in H1 2027.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.